Keep up with the latest in the tableting community!
May 22, 2023
Oral dosage specialist CDMO Skyepharma Productions S.A.S. (Skyepharma) has collaborated with Bordeaux University to study the influence of geometrical and process parameters on the release attributes of press-coated tablets. The work potentially enables oral solid dose (OSD) forms to vary lag-time ingredient release profiles while retaining a constant formulation.
Key points for the study:
*Influence of process parameters
*Observing opening modes
*Alternative drug release adjustment
Full news available here.
To know more about controlled
release, request access to our webinar replay on tab-in-tab formulations on STYL’One Evo
Access webinar replay
#controlled release #lag-time #release kinetics #press-coated tablets #OSD
May 15, 2023
Key challenges of development and commercial manufacturing of oral solid dosage forms:
2 key trends can currently be identified in the pharmaceutical market:
Differentiated technologies for complex therapeutic systems and better bioavailability
Most of the drug substances in research and development belong to biopharmaceutical classification system (BCS) class II (low solubility / high permeability) and IV (low solubility / low permeability). To formulate these substances as solid dosage forms, three key technology solutions have been successfully applied:
The formation of amorphous solid dispersions has been gaining increasing attention in the last decade. Key technologies to generate amorphous solid dispersions are Hot Melt Extrusion, spray drying or co-precipitation.
In the field of complex solid dosage forms, intelligently encapsulated mini tablet systems (EMTS, see photo 1) or multi-unit pellet systems (MUPS) can control the release of the active ingredient(s).
Challenges in the development and production of HPAPIs
HPAPIs are on the rise and will play an important role in drug therapy in the future. The development and production of drugs with HPAPIs in the field of oncology is highly complex and often must be achieved under time pressure, as many of these new molecular entities (NMEs) are approved as "breakthrough therapy" in a fast-track process to quickly meet the high medical demand.
Three pillars for safe and efficient handling of HPAPIs:
Access the full news here.